



Legal Division/PATENT
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

Facsimile Transmission

CONFIDENTIAL

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone call to the sender named below. Thank you.

To:
U.S. PATENT OFFICE Art Unit 1621

RECEIVED
CENTRAL FAX CENTER

Location: Washington, D.C.

~~FEB 01 2006~~

Facsimile Telephone: **571-273-8300 (571-272-9950)**

No. of Pages: (including this page) 5

From: **Jason G. Tebbutt, Esq.**

Department Name:	Legal Division/PATENT	Charge No.:	88421
------------------	-----------------------	-------------	-------

Facsimile Telephone: (212) 573-1939

Date: February 1, 2006	Time (New York) 1:00 PM
------------------------	-------------------------


TO CONFIRM RECEIPT OF TRANSMISSION, CALL 212 573-3189

COMMENT: Application No. 10/706,694
Attorney docket PC23299A

Patent Application 10/706,694
Attorney Docket No. PC23299A

I hereby certify that this correspondence is being transmitted by facsimile transmission to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of February 2006 at Facsimile No. 571-273-8300.

By _____


(Signature of person faxing)
Jason G. Tebbutt

(Typed or printed name of person)

RECEIVED
CENTRAL FAX CENTER

FEB 01 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: WATSON, ET AL. :

APPLICATION NO.: 10/706,694 : Examiner: ZUCKER, PAUL A

FILING DATE: November 12, 2003 : Group Art Unit: 1621

TITLE: A METHOD FOR PREPARING INDAN- :
1,3-DICARBOXYLIC ACID

Mail Stop _____

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.97(i)

This disclosure statement under 37 C.F.R. 1.97 & 1.98 is being submitted after payment and recording of the issue fee. Applicant(s) petition the Commissioner to direct the Examiner to consider this Information Disclosure Statement. This disclosure statement is submitted in order that the Patent and Trademark Office may consider the relevancy of certain information to the invention described and claimed in the subject application. Enclosed are copies of the following:

a) The English Abstract of JP2001-114724, cited by the Russian Patent Office on Dec. 5, 2005.


Patent Application 10/706,694
Attorney Docket No. PC23299A

REMARKS

The undersigned certifies that each item of information contained in this disclosure statement was first cited in a communication from a foreign patent office.

Applicants believe no fee is due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge any fees required to Deposit Account No. 16-1445.

Date: February 1, 2006



Jason G. Tebbutt
Attorney for Applicant(s)
Reg. No. 55,671

Pfizer Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-4827